Sofdra™ (sofpironium) topical gel, 12.45% is now approved in the US
Our lead dermatology product, Sofdra, is approved for use by the US Food and Drug Administration (FDA).
Mature pipeline of dermatology and antimicrobial products—including Sofdra, an FDA-approved treatment.
World-class team with extensive dermatology drug development and commercialisation expertise.
Global healthcare innovator, poised to transform the most underserved and lucrative markets.
Here at Botanix, we are at the forefront of dermatological innovation. With a world-class team and significant capital, we are committed to addressing common yet underserved skin diseases and infections.
As an ASX-listed company, we are in a prime position to develop and commercialise groundbreaking treatments across broad markets, all while adhering to the highest clinical standards set by the US FDA.
Check out our latest news
https://botanixpharma.com/wp-content/uploads/EP-report.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-07-11 20:22:232024-07-11 20:22:24“Potentially Disruptive” | E&P Analysis
https://botanixpharma.com/wp-content/uploads/Euroz-hartleys.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-07-10 20:36:402024-07-10 20:36:40Euroz Hartleys Upgrades BOT to Buy
https://botanixpharma.com/wp-content/uploads/Cap-Raise.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-06-21 01:37:462024-06-21 01:37:46Botanix secures commitments for $70 million
https://botanixpharma.com/wp-content/uploads/Approval.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-06-20 00:03:202024-06-21 17:50:06FDA Approves Sofdra™ topical gel
https://botanixpharma.com/wp-content/uploads/Business.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-06-12 00:23:572024-06-12 00:29:46Final Sofdra™ Labelling Discussions with FDA
https://botanixpharma.com/wp-content/uploads/EP-Analyst-note.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-05-21 20:45:562024-05-21 20:45:57“Compelling Opportunity” | E&P Research Report
https://botanixpharma.com/wp-content/uploads/Euroz-hartley.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-05-13 22:19:362024-05-13 22:20:15Euroz Hartleys Analysis | Commercial Day Webinar
https://botanixpharma.com/wp-content/uploads/Commercial-Plan.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-05-13 22:16:282024-05-13 22:16:29Video Available | Commercial Day Webinar
“Compelling Opportunity” | E&P Research Report
May 21, 2024
In new research on Botanix, leading biotech analyst David Nayagam…
Euroz Hartleys Analysis | Commercial Day Webinar
May 13, 2024
Euroz Hartleys’ Seth Lizee reviews the Botanix Commercial…
Video Available | Commercial Day Webinar
May 13, 2024
Video is now available of the Company’s Commercial Day Webinar…
Botanix Included in the All Ordinaries Index
April 5, 2024
Botanix Pharmaceuticals (ASX:BOT) is honoured to announce the…
